title: Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
abstract: OBJECTIVE
  To study the role of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in monitoring the response of bone metastases to endocrine therapy combined with bisphosphonates in patients with breast cancer.
  
  
  METHODS
  Ten breast cancer patients with bone metastases who were to receive endocrine therapy and bisphosphonates were investigated prospectively by DCE-MRI. We chose a reference lesion for each patient who was studied at baseline, within 3 weeks from the second administration of bisphosphonates, and after 4 and 8 months from the initiation of medical treatment. Time/intensity curves, representing temporal changes of signal intensity in areas of interest in the context of the target lesions (ROI), were obtained for each DCE-MRI.
  
  
  RESULTS
  Changes in the shape of the T/I curves suggesting tumor regression were seen shortly after the initiation of medical treatment in the three patients who had the most durable responses.
  
  
  CONCLUSIONS
  DCE-MRI has the potential to detect early changes related to medical treatment in bone metastases from breast cancer. If confirmed in larger series, these data identify DCE-MRI as a diagnostic tool for evaluating new bone targeting antineoplastic agents.
authors.affiliation: Units of Medical Oncology, Diagnostic Imaging and Radiation Therapy, Institute for Cancer Research and Treatment, IRCC, Candiolo, Torino, Italy. fmontemurro@ircc.mauriziano.it
authors.forename: F
authors.initials: F
authors.lastname: Montemurro
authors.forename: F
authors.initials: F
authors.lastname: Russo
authors.forename: L
authors.initials: L
authors.lastname: Martincich
authors.forename: S
authors.initials: S
authors.lastname: Cirillo
authors.forename: M
authors.initials: M
authors.lastname: Gatti
authors.forename: M
authors.initials: M
authors.lastname: Aglietta
authors.forename: D
authors.initials: D
authors.lastname: Regge
mesh_terms: D000328:Adult; D000368:Aged; D000077384:Anastrozole; D001859:Bone Neoplasms / Q000473:pathology* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D000077289:Letrozole; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use; D000077268:Pamidronate; D010865:Pilot Projects; D011446:Prospective Studies; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D017273:Goserelin; D000077384:Anastrozole; D000077211:Zoledronic Acid; D000077289:Letrozole; D000077268:Pamidronate